Immunoblastic Lymphadenopathy clinical trials
The registry lists 272 studies for Immunoblastic Lymphadenopathy across more than 10 countries. 13 are recruiting or about to start. 15 of them are mainly about Immunoblastic Lymphadenopathy (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-09.
Get an email when these change. Save the Immunoblastic Lymphadenopathy studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Who runs them
National Cancer Institute (NCI) (43) · Fred Hutchinson Cancer Center (15) · Mayo Clinic (12) · City of Hope Medical Center (10) · Memorial Sloan Kettering Cancer Center (10) · M.D. Anderson Cancer Center (8) · Northwestern University (7) · Case Comprehensive Cancer Center (7)
What is being tested here
Drugs under test in Immunoblastic Lymphadenopathy studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
| Drug | Open | Phase 3 | All |
|---|---|---|---|
| Azacitidine | 2 | 1 | 6 |
| Duvelisib | 2 | 1 | 2 |
| Cyclophosphamide | 1 | 2 | 16 |
| Cc-486 | 1 | 1 | 2 |
| Abatacept | 1 | 0 | 1 |
| Fenretinide | 1 | 0 | 1 |
| Soquelitinib | 1 | 1 | 1 |
| Cemiplimab | 1 | 0 | 1 |
| Golidocitinib | 1 | 1 | 1 |
| Fludarabine phosphate | 0 | 1 | 17 |
Drug classes tested here Antimetabolites 2 open · Tyrosine kinase inhibitors (TKIs) 2 open · Alkylating agents 1 open · Immune checkpoint inhibitors 1 open · HDAC inhibitors 25
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
All 3, phase 3 first
- Nov 2027Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma · Phase 3 · Corvus Pharmaceuticals, Inc.
- Mar 2027Azacitidine and Abatacept in Relapsed or Refractory T-Cell Lymphoma · National Cancer Institute (NCI)
- May 2027Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma · Alliance for Clinical Trials in Oncology
Who these studies take
Of the 12 Immunoblastic Lymphadenopathy studies recruiting now, 9 (75%) set no upper age limit and 1 (8%) stop at 75 or younger. 1 (8%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 0 (0%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 1 (8%) | 1 (8%) |
| 18 | 11 (92%) | 11 (92%) |
| 30 | 11 (92%) | 11 (92%) |
| 40 | 11 (92%) | 11 (92%) |
| 50 | 11 (92%) | 11 (92%) |
| 65 | 12 (100%) | 12 (100%) |
| 75 | 12 (100%) | 12 (100%) |
| 85 | 11 (92%) | 11 (92%) |
Across all 272 studies, recruiting or not: 22% stop at 75 or younger and 11% at 65; 23% take children; 0% are for women only and 0% for men only; 1% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
How long Immunoblastic Lymphadenopathy studies take
Of 19 phase 1 interventional studies under Immunoblastic Lymphadenopathy, half reached primary completion within 58 months of starting, counting those still running.
| Start to primary completion | Every sponsor | Industry | Non-industry |
|---|---|---|---|
| Phase 1 | 58 mo45–71 · 19 studies | — | — |
| Phase 2 | 64 mo43–97 · 17 studies | — | — |
Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out
Studies
Recruiting first, then most recently updated. Showing 50 of 272. Browse all 272 → or search them.
- Azacitidine and Abatacept in Relapsed or Refractory T-Cell LymphomaRecruitingNCT07388563Phase 11 country
- Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell LymphomaRecruitingNCT04803201Phase 21 country
- Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic CancerRecruitingNCT011376431 country
- Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin LymphomaRecruitingNCT04234048Phase 11 country
- Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell LymphomaRecruitingNCT06561048Phase 33 countries
- A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.RecruitingNCT06393738Phase 15 countries
- Registry of Older Patients With CancerRecruitingNCT011378251 country
- A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or LymphomaRecruitingNCT03017820Phase 11 country
- A Registry for People With T-cell LymphomaRecruitingNCT059781411 country
- A Study of Duvelisib Versus Gemcitabine or Bendamustine in Participants With Relapsed/Refractory Nodal T Cell Lymphoma With T Follicular Helper (TFH) PhenotypeRecruitingNCT06522737Phase 310 countries
- Golidocitinib Versus Placebo as Maintenance Therapy for Peripheral T-Cell LymphomaRecruitingNCT07300514Phase 31 country
- Clinical Study of Mitoxantrone Liposome and Azacitidine in the Treatment of R/R AITLRecruitingNCT06224842Phase 1/21 country
- A Retrospective Study on Extranodal Lymphoma or Lymphoma of Rare Pathological TypesNot yet recruitingNCT059074471 country
- Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell LymphomaActive, not recruitingNCT03113500Phase 22 countries
- Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid TumorsTerminatedNCT00788125Phase 1/21 country
- Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell LymphomasActive, not recruitingNCT03598998Phase 1/21 country
- Study of Pembrolizumab (MK-3475) in Combination With RomidepsinCompletedNCT03278782Phase 1/21 country
- Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell TransplantActive, not recruitingNCT011995621 country
- A Phase I Trial Anti-CC Chemokine Receptor 4 Chimeric Antigen Receptor T Cells (CCR4 CAR T Cells) for CCR4 Expressing T-cell Malignancies Including Peripheral T-cell Non-Hodgkin Lymphoma (PTCL) and Cutaneous T-cell Non-Hodgkin Lymphoma (CTCL)SuspendedNCT07055477Phase 11 country
- A Study to Assess the Safety, Tolerability, Efficacy, and Drug Levels of BMS-986369 (Golcadomide) in Participants With Relapsed or Refractory T-cell Lymphomas in Japan (GOLSEEK-3)Active, not recruitingNCT06035497Phase 1/21 country
- Ro Plus CHOEP as First Line Treatment Before HSCT in Young Patients With Nodal Peripheral T-cell LymphomasCompletedNCT02223208Phase 1/21 country
- 3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With CancerActive, not recruitingNCT009350901 country
- Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic MalignanciesSuspendedNCT05377827Phase 11 country
- Cholecalciferol in Improving Survival in Patients With Newly Diagnosed Cancer With Vitamin D InsufficiencyActive, not recruitingNCT01787409Not applicable1 country
- Romidepsin and Lenalidomide in Treating Patients With Previously Untreated Peripheral T-Cell LymphomaCompletedNCT02232516Phase 21 country
- Donor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other DisordersActive, not recruitingNCT00544115Phase 2
- Efficacy and Safety of Oral Azacitidine Compared to Investigator's Choice Therapy in Patients With Relapsed or Refractory AITLCompletedNCT03593018Phase 35 countries
- Tazemetostat Plus CHOP in 1L T-cell LymphomaWithdrawnNCT06692452Phase 2
- Phase I/II Study Evaluating AUTO4 in Patients With T Cell Receptor Beta Constant (TRBC)1 Positive T Cell LymphomaTerminatedNCT03590574Phase 1/22 countries
- A Phase 1b/2 Study of Intravenous Brincidofovir in Patients With Relapsed or Refractory Lymphoma and Relapsed or Refractory Extranodal Natural Killer/T-cell LymphomaSuspendedNCT06761677Phase 1/23 countries
- A Phase II Study of Single Agent Brentuximab Vedotin in Relapsed/Refractory CD30 Low (<10%) Mature T Cell Lymphoma (TCL)CompletedNCT02588651Phase 21 country
- Clinical Study of CEP+Dasatinib + Azacytidine in First-line Treatment of. Angioimmunoblastoma ForesightActive, not recruitingNCT07046182Phase 41 country
- Anti-CD7 CAR-T Cell Therapy for Relapse and Refractory CD7 Positive T Cell MalignanciesCompletedNCT05290155Phase 11 country
- Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK-cell NeoplasmsCompletedNCT03493451Phase 25 countries
- CPI-613 and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma or Hodgkin LymphomaCompletedNCT02168140Phase 11 country
- Ipilimumab and Local Radiation for Selected Solid TumorsTerminatedNCT01769222Phase 11 country
- Combination Chemotherapy & Lenalidomide in Newly Diagnosed Stage II-IV Peripheral T-cell Non-Hodgkin's LymphomaCompletedNCT02561273Phase 1/21 country
- Use of Venetoclax as Single Agent in Patients With Relapsed/Refractory BCL-2 Positive Peripheral T Cell LymphomaTerminatedNCT03552692Phase 21 country
- Anti-TRBC1 CAR-T Cell Therapy in Patients With TRBC1 Positive T Cell MalignanciesSuspendedNCT04828174Phase 11 country
- Cardiac Magnetic Resonance Imaging in Patients With Non-Hodgkin Lymphoma or Hodgkin Lymphoma Receiving DoxorubicinCompletedNCT005777981 country
- Brentuximab Vedotin and Pembrolizumab in Treating Patients With Recurrent Peripheral T-Cell LymphomaWithdrawnNCT04795869Phase 21 country
- Combination Chemotherapy and Pralatrexate as First-Line Therapy in Treating Patients With Non-Hodgkin LymphomaCompletedNCT01336933Phase 21 country
- Carfilzomib in Treating Patients With Relapsed or Refractory T-Cell LymphomaCompletedNCT01336920Phase 11 country
- Chemotherapy Before Autologous Stem Cell Transplantation +/- Rituximab in Relapsed or Refractory Aggressive Non-Hodgkin's LymphomaCompletedNCT00078949Phase 33 countries
- Cyclosporine in Treating Patients With Recurrent or Refractory Angioimmunoblastic T-Cell LymphomaTerminatedNCT00070291Phase 21 country
- Physician-Initiated Stop-Smoking Program for Patients Receiving Treatment for Early-Stage CancerCompletedNCT00002520Not applicable1 country
- Chemotherapy Plus PD-1 Monoclonal Antibody in the Treatment of Refractory or Relapsed Peripheral T-cell Lymphoma.Status unknownNCT05821192Not applicable1 country
- Oral Clofarabine for Relapsed/Refractory Non-Hodgkin LymphomaCompletedNCT00644189Phase 1/21 country
- T Cells Expressing a Fully-Human Anti-CD30 Chimeric Antigen Receptor for Treating CD30-Expressing LymphomasCompletedNCT03049449Phase 11 country
- Panobinostat in Treating Patients With Relapsed or Refractory Non-Hodgkin LymphomaCompletedNCT01261247Phase 21 country